ZARVUMYS Trademark

Trademark Overview


On Wednesday, July 31, 2019, a trademark application was filed for ZARVUMYS with the United States Patent and Trademark Office. The USPTO has given the ZARVUMYS trademark a serial number of 88554954. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, January 23, 2023. This trademark is owned by Eli Lilly and Company. The ZARVUMYS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis
zarvumys

General Information


Serial Number88554954
Word MarkZARVUMYS
Filing DateWednesday, July 31, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, January 23, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 22, 2019

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, August 15, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Monday, January 23, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, January 23, 2023ABANDONMENT - NO USE STATEMENT FILED
Wednesday, May 25, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, May 24, 2022SOU EXTENSION 5 GRANTED
Wednesday, May 18, 2022SOU EXTENSION 5 FILED
Wednesday, May 18, 2022TEAS EXTENSION RECEIVED
Tuesday, November 9, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, November 8, 2021SOU EXTENSION 4 GRANTED
Friday, November 5, 2021SOU EXTENSION 4 FILED
Friday, November 5, 2021TEAS EXTENSION RECEIVED
Wednesday, May 19, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, May 17, 2021SOU EXTENSION 3 GRANTED
Monday, May 17, 2021SOU EXTENSION 3 FILED
Monday, May 17, 2021TEAS EXTENSION RECEIVED
Thursday, November 19, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, November 17, 2020SOU EXTENSION 2 GRANTED
Tuesday, November 17, 2020SOU EXTENSION 2 FILED
Tuesday, November 17, 2020TEAS EXTENSION RECEIVED
Wednesday, June 24, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, June 23, 2020SOU EXTENSION 1 GRANTED
Wednesday, June 3, 2020SOU EXTENSION 1 FILED
Monday, June 22, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, June 3, 2020TEAS EXTENSION RECEIVED
Tuesday, December 17, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, October 22, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 22, 2019PUBLISHED FOR OPPOSITION
Wednesday, October 2, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, September 12, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, September 11, 2019ASSIGNED TO EXAMINER
Thursday, August 15, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, August 3, 2019NEW APPLICATION ENTERED